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Abstract  The  number  of  bronchiectasis  diagnoses  has  increased  in  the  last  two  decades  due
to several  factors.
Research  carried  out  over  the  last  years  showed  that  an  aetiological  diagnosis  could  change
the approach  and  treatment  of  a  relevant  percentage  of  patients  and  consequently  the  prog-
nosis.
Currently,  systematic  investigation  into  aetiology,  particularly  of  those  disorders  that  can  be
subject to  speciﬁc  treatment,  is  recommended.
Given  the  complexity  of  the  aetiological  diagnosis,  the  Pulmonology  Portuguese  Society
Bronchiectasis  Study  Group  assembled  a  working  group  which  prepared  a  document  to  guide
and standardize  the  aetiologic  investigation  based  on  available  literature  and  its  own  exper-
tise. The  goal  is  to  facilitate  the  investigation,  rationalize  resources  and  improve  the  delivery
of care,  quality  of  life  and  prognosis  of  patients  with  bronchiectasis.sa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
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Rationale
Bronchiectasis  (BE)  is  characterized  by  irreversible  airways
dilatation  and  lesion  associated  with  a  vicious  cycle  of
inﬂammation,  recurrent  infection  and  progressive  bronchial
damage.
In  the  last  few  years  there  have  been  many  signs  of  a
renewed  interest  in  this  pathology  due  to  its  prevalence
which  had  not  decreased  in  response  to  a  better  control
of  respiratory  infections  as  would  be  expected.  This  fact
is  mainly  due  to  a  better  diagnostic  capacity,  the  recog-
nition  of  the  association  between  BE  and  some  systemic
pathologies  and  also  to  the  increase  in  the  population
survival  rates,  namely  chronic  patients.  Therefore,  BE  epi-
demiological  characteristics  have  been  changing,  with  less
post-infectious  BE,  more  adult  patients  and  more  cases  asso-
ciated  with  other  prevalent  diseases  like  chronic  obstructive
lung  disease  (COPD).1,2
BE  can  result  from  several  local  or  systemic  inherited  or
acquired  diseases.  In  a  signiﬁcant  number  of  cases  aetiol-
ogy  cannot  be  deﬁned,  even  after  an  extensive  evaluation.
Therefore,  the  percentage  of  diagnoses  obtained  varies
widely  in  published  series.3--5
Obtaining  an  aetiologic  diagnosis  is  often  considered
unnecessary  and  non-cost  effective.6 However,  there  are
several  reasons  why  one  should  investigate  aetiology:
•  The  speciﬁc  treatment  of  certain  diseases  causing  BE
relates  to  a  better  prognosis.3,4,7
•  The  presence  of  BE  worsens  the  underlying  disease  prog-
nosis,  accelerates  loss  of  pulmonary  function,  increases
mortality  and  signiﬁcantly  reduces  quality  of  life.8,9
•  The  diagnosis  of  hereditary  diseases  is  important  to  assess
transmission  risk  and  offer  genetic  counselling
•  BE  is  a  complex,  heterogeneous  and  possibly  a  multifac-
torial  entity.10
•  Some  drugs  used  in  cystic  ﬁbrosis  (CF)  are  ineffective,
even  harmful,  in  non-cystic  ﬁbrosis  BE,11 thus  aetiology
should  be  considered  in  the  analysis  of  clinical  trials
because  it  may  inﬂuence  ﬁnal  results
•  A  clearly  deﬁned  idiopathic  BE  patients  group  will  help
underlying  mechanisms  investigations
In  conclusion,  after  diagnosing  BE  a  systematic  aetiologic
investigation  should  be  undertaken.
The  Pulmonology  Portuguese  Society  Bronchiectasis
Study  Group  convened  a  working  group  which  prepared  a
document  to  guide  and  standardize  the  aetiologic  investiga-
tion  based  on  available  literature  and  its  own  experience.
The  goal  is  to  rationalize  resources  and  improve  the  delivery
of  care,  quality  of  life  and  prognosis  of  patients  with  BE.
Aetiological investigations
A  systematic  investigation  of  the  underlying  aetiology  under-
taken  according  to  a  predetermined  algorithm  increases  the
likelihood  of  obtaining  a  diagnosis  with  better  resource  man-
agement.
In  order  to  establish  the  most  likely  hypotheses  and  carry
out  the  most  effective  tests,  the  initial  assessment  must  be
l
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uided  by  a  detailed  clinical  history  and  physical  examina-
ion.
linical  history
linical  history  should  include  onset  age,  presenting  symp-
oms,  clinical  evolution,  previously  diagnosed  diseases,  risk
xposures,  infertility  history,  non-respiratory  symptoms  and
amily  history  including  consanguinity  data  (Table  1).  These
uestions  should  be  asked  in  a  systematic  way  as  patients
ay  not  value  certain  clinical  data  either  because  they  do
ot  signiﬁcantly  compromise  their  quality  of  life  or  because
hey  are  not  aware  of  their  relevance  for  the  diagnosis.
magiology  and  microbiology
he  results  of  sputum  microbiological  examination  as  well
s  imaging  features,  in  particular  the  location  of  BE  (Fig.  1)
re  also  data  to  be  taken  into  consideration.
etiologic  diagnosis
t  is  common  to  assume/that  the  diagnosis  is  post-infectious
E  when  symptoms  begin  after  a  serious  infection.  Neverthe-
ess,  there  are  cases  where  symptoms  occur  only  years  later
hen  another  predisposing  factor  is  established  (for  exam-
le,  some  degree  of  immunodeﬁciency).  On  the  other  hand,
ne  should  ask  the  patient  about  respiratory  symptoms  aris-
ng  before  the  infectious  episode  as  they  may  be  related  to
he  ﬁrst  exacerbation  of  undiagnosed  BE.  Therefore,  despite
he  fact  that  infectious  diseases  are  still  a  frequent  cause  of
E,3--6,10 care  should  be  taken  in  establishing  the  diagnosis
f  post-infectious  BE  especially  in  the  presence  of  upper  air-
ay  symptoms,  non-respiratory  symptoms  or  other  systemic
iseases  previously  diagnosed.
If  after  proper  investigation  aetiology  is  still  not  deﬁned,
t  is  important  to  be  aware  of  new  clinical  data  through-
ut  the  follow  up  that  may  require  a  reassessment.  In  some
ystemic  diseases,  such  as  inﬂammatory  bowel  disease  and
heumatoid  arthritis,  BE  may  precede  its  diagnosis.12,13 In
ther  situations,  there  may  be  an  evolution  over  the  years
for  instance,  a  patient  with  IgA  deﬁciency  may  progress  to
ommon  variable  immunodeﬁciency).14
In  certain  cases,  where  aetiologic  diagnoses  are  consid-
red  of  exclusion,  investigation  has  to  be  rigorous.
It  would  be  impossible  to  address  investigation  of  all
auses  of  BE  in  this  document,  so  only  those  that  currently
eneﬁt  from  speciﬁc  monitoring  and  treatment  strategies
ith  prognostic  implications  have  been  included.
lpha-1-antitrypsin deﬁciency
eﬁnition
lpha-1-antitrypsin  (AAT)  is  a  glycoprotein,  mainly  produced
n  the  liver  and  functions  to  protect  the  lung  against  proteo-
ytic  damage  being  a  highly  effective  inhibitor  of  neutrophil
lastase.
AAT  deﬁciency  (AATD)  is  deﬁned  by  a reduced  concentra-
ion  of  AAT  in  the  serum  and/or  identiﬁcation  of  a  defective
224  Original  article
Table  1  Clinical  characteristics  and  aetiology.
Aetiologic  clinical  history  Disease
Symptoms  onset  age
Neonatal  period
childhood
Adult  life  (>40  years)
Old  women
PCD,  CF
CF
Idiopathic  BE
NTM
Chronic symptoms  since  onset  Idiopathic  BE
Smoking history,  occupational  exposures  COPD,  toxic  inhalation,  NTM
Infection  history  Measles,  whooping  cough,  pneumonia,  PT
Chronic sinusitis PCD,  CF,  Young’s  syndrome,  DPB,  yellow  nail  syndrome,
idiopathic  BE
Nasal polyps CF,  asthma
Recurrent  otitis  media;  hearing  loss  PCD
Subfertility  and  infertility  PCD,  CF/CFTR-RD,  Young’s  syndrome
Susceptibility  to  infection  (in  other  organs)  Immunodeﬁciencies  (primary  or  secondary)
Gastrointestinal  symptoms
Diarrhoea
Malabsortion  symptoms
Chronic  pancreatitis/recorrent  acute  pancreatitis
Pyrosis
IID
CF
CF/CFTR-RD
GERD
Gastric  band  Aspiration
Previously  diagnosed  diseases  COPD,  asthma,  connective  tissue  diseases,  autoimmune
diseases,  IID
Severe asthma  ABPA
Family history
Hereditary  diseases/consanguinity PCD,  CF,  Primary  immunodeﬁciencies
Sputum characteristics
Scarce
Brown  plugs
Nodular-bronchiectatic  NTM--PD
ABPA
Ethnic origin  DPB
PCD, primary ciliary disease; CF, cystic ﬁbrosis; DPB, diffuse panbronchiolitis; CFTR-RD, cystic ﬁbrosis transmembrane regulator-related
disease; IID, intestinal inﬂammatory disease; NTM-PD, non-tuberculosis mycobacteria-pulmonary disease; ABPA, aspergilosis bronchopul-
monary allergic; PT, pulmonary tuberculosis.
Bronchiectasis
Located
PT sequelae,
intrinsic or  extrinsic
obstruction
Diffuse
Peripheral
UL predominance
Typical CF
PT seq uela e
ML/lingular
predominance
NTM
PCD
LL predo minance
Idiopathic BE
immunodeficien-
cies PCD;  COPD
Central
ABPA
Williams-Camp bell
syndrome
Figure  1  Radiological  characteristics  and  aetiology.  UL,  upper  lobe;  ML,  middle  lobe;  LL,  lower  lobe.
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•Recommendations  for  aetiological  diagnosis  of  bronchiectas
genotype.  It  is  not  a  rare  disease,  but  it  is  one  that  is
underdiagnosed.15 Severe  AATD  affects  approximately  1  in
2000  to  1  in  5000  individuals.
Protease  inhibitor  (PI)  M  is  the  normal  allele,  while  the
two  most  frequent  deﬁcient  alleles  are  PI*S  and  PI*Z.  The
PI*Z  prevalence  is  higher  in  northern  and  western  European
countries  whereas  the  PI*S  prevalence  is  higher  in  south-
western  European  countries.  Portugal  has  one  of  the  highest
estimated  PI*S  frequency  in  the  world  (185.1/1000)  with  also
a  high  PI*Z  frequency  (29.7/1000).16
Clinical  features
AATD  is  the  only  established  genetic  risk  factor  for  COPD,  and
it  predisposes  to  severe  emphysema.  It  may  also  cause  liver
disease  and,  less  frequently,  vasculitis  and  panniculitis.17
The  high  degree  of  overlap  between  COPD  and  AATD  is
a  confounder  when  making  a  clinical  diagnosis.  The  most
common  pulmonary  symptoms  in  patients  with  AATD  include
dyspnoea,  cough,  sputum  expectoration,  wheezing  and  fre-
quent  exacerbations.
Distinctive  and  suggestive  features  of  the  emphysema
associated  with  AATD  may  include:
• Early  onset  (in  the  fourth  and  ﬁfth  decades)
•  Emphysema  out  of  proportion  to  risk  factors  (e.g.  tobacco
smoking,  occupational  exposure)
•  Panacinar  pathology
•  Disproportionate  emphysematous  involvement  of  the  lung
bases
Although  these  suggestive  features,  there  are  no  clinical
characteristics  that  reliably  distinguish  COPD  from  AATD.
Diagnostic  criteria
AATD  diagnosis  is  based  in  laboratory  data.
Three  strategies  are  commonly  used  to  diagnose  AATD:
measurement  of  the  serum  or  plasma  protein  level,  AAT  pro-
tein  phenotyping  of  serum  or  plasma,  and  AAT  genotyping.
If  the  AAT  protein  level  is  below  the  normal  range,  further
assessment  with  protein  phenotyping  or  genotyping  is  rec-
ommended.
As  AAT  is  an  acute  phase  protein,  serum  concentrations
can  be  used  reliably  for  diagnostic  testing  only  if  no  inﬂam-
mation  is  present  at  the  time  the  blood  sample  is  drawn.
A  new  diagnostic  tool,  the  AlphaKit  QuickScreen®,
directly  detects  the  Z  protein  in  a  sample  of  blood.  It  is
a  screening  test  (a  positive  indicates  the  need  for  pheno-
typing  or  genotyping)  that  can  be  performed  during  a  clinic
visit  with  results  available  in  15--30  min.  It  has  considerable
potential  to  increase  the  overall  AATD  detection  rate.
Prevalence  of  BE  in  AATD
The  role  of  AATD  in  the  aetiology  of  BE  has  been  the  subject
of  debate  and  contention  over  the  years.18
An  association  was  postulated  after  a  number  of  case
reports  has  linked  severe  (PI*ZZ  phenotype)  AATD  to  BE  in
individual  or  small  numbers  of  cases.  In  these  reports  the
•225
ncidence  of  BE  in  patients  with  AATD  was  remarkably  simi-
ar,  with  a  common  overall  estimate  of  about  40%.19--21
However,  isolated  case  reports  cannot  provide  any  causal
ink  between  these  two  conditions.  Moreover,  some  of  these
atients  had  other  clinical  conditions  potentially  leading  to
E.22
A  case-control  study  indicates  that  AAT  phenotype  dis-
ribution  and  gene  frequencies  are  not  different  between
atients  with  bronchiectasis  and  control  subjects.22 How-
ver,  this  study  highlights  the  importance  of  bronchiec-
asis  associated  emphysema.  The  authors  show  that
ronchiectatic  patients  without  emphysema  do  not  have  a
ifferent  AAT  distribution  as  compared  with  control  subjects
n  contrast  to  bronchiectatic  patients  with  emphysema.
his  suggests  that  bronchiectasis  may  be  a  consequence
f  emphysema  in  PI*Z  patients  rather  than  a  primary
ause.22
One  small  case-control  study  reported  a  possible
ncreased  frequency  of  the  Z  allele  among  patients  with
ronchiectasis  and  common  variable  immunodeﬁciency.23
wo  other  studies  suggest  that  immune  deﬁciency  may
ombine  with  selected  AATD  phenotypes  to  elicit  clinically
igniﬁcant  bronchiectasis.10,24
Parr  et  al.  have  demonstrated  that  27%  of  74
AT-deﬁcient  patients  had  High-Resolution  Computed  Tomo-
raphy  (HRCT)  evidence  of  BE.  That  study  indicated  a
oncordance  distribution  of  airway  disease  and  emphysema
ith  greater  severity  demonstrated  in  the  lower  lung.  This
oncordance  may  reﬂect  the  inﬂuence  of  a ﬁeld  effect  on  a
ommon  pathogenic  mechanism  or  may  indicate  that  there
s  an  interaction  between  the  inﬂammatory  processes  that
re  considered  to  be  putative  in  each  condition.  BE  may  be
 consequence  of  emphysema,  as  previously  suggested,  but
he  reverse  mechanism  is  equally  plausible.25
The  Canadian  guidelines  say  that  there  is  insufﬁcient  evi-
ence  in  the  literature  to  support  routine  targeted  testing
or  AATD  in  individuals  with  BE.26
In  a  recent  publication  the  REDAAT  (Spanish  registry  of
atients  with  AATD)  group  suggests  that  in  patients  with
E  the  AAT  serum  concentration  should  not  be  assessed  by
outine  processes,  but  individualized.27
Further  studies  with  a  larger  number  of  patients  are
equired  to  conﬁrm  the  relationship  between  AATD  and  BE
nd  establish  guidelines  with  a  stronger  evidence  level.
In  the  context  of  the  mixed  results  reported  in  the
iterature,  the  high  frequency  of  deﬁcient  alleles  in  the  Por-
uguese  population,  and  the  beneﬁt  from  early  detection  of
ATD  (behaviour  modiﬁcation,  optimized  clinical  manage-
ent,  existence  of  speciﬁc  treatment  for  selected  patients
nd  genetic  counselling)  it  was  the  consensus  of  the  Work-
ng  Group  that  testing  for  AATD  should  be  undertaken  in  all
ndividuals  with  BE.
AATD  may  play  a  role  which  is  contributory  to,  and  cumu-
ative  with  other  diseases  as  the  aetiology  of  BE.
ecommendations
 Screening  for  AATD  should  be  made  in  all  patients  with
BE.
 If  AAT  protein  level  is  below  the  normal  range,  further
assessment  with  protein  phenotyping  or  genotyping  is  rec-
ommended.
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rimary ciliary dyskinesia
eﬁnition
rimary  ciliary  dyskinesia  (PCD)  is  a  rare,  heterogeneous
utosomal  recessive  genetic  disorder  with  an  estimated  inci-
ence  of  1  per  10,000--20,000  births.28 It  is  characterized
y  abnormal  ciliary  ultrastructure  or  function,  with  wide
linical  spectrum  frequently  involving  recurrent  respiratory
nfection  due  to  defective  mucociliary  clearance.29 Inheri-
ance  usually  follows  autosomal  recessive  pattern.30
linical  features
ge  at  presentation  range  from  birth  to  adulthood.  Pre-
enting  symptoms  according  to  age  are:30--32
 In  the  newborn  period
◦  Neonatal  respiratory  distress  or  pneumonia  without  any
obvious  predisposing  factors
◦  Continuous  rhinorrhea  from  the  ﬁrst  day  of  life
◦  Associated  features:  disorders  of  laterality,  complex
congenital  heart  disease,  heterotaxy,  hydrocephalus,
cleft  palate,  bilateral  cervical  ribs,  biliary  atresia,
esophageal  abnormalities,  anal  atresia
 In  the  infants  and  older  children
◦  Chronic  productive  cough,  recurrent  upper  and  lower
respiratory  tract,  BE
◦  Chronic  rhinosinusitis  (rarely  nasal  polyps)
◦  Recurrent  otitis  media  with  effusion,  hearing  loss
 In  the  adults
◦  Same  as  for  children
◦  Nasal  polyposis  and  halitosis
◦  Ectopic  pregnancy,  subfertility  in  females;  infertility  in
males  (50%)
iagnostic  criterian  practice,  patients  with  clinical  picture  suggestive  of
CD  should  be  screened,  and  diseases  with  similar  fea-
ures  (e.g.  CF,  immunodeﬁciency)  excluded.  Any  positive
creening  testing  requires  conﬁrmatory  diagnostic  testing  to
t
d
c
Table  2  Screening  and  diagnostic  test  for  PCD.
Screening  test  Nasal  nitric  oxide  (NO)  assay  
Diagnostic test  Analysis  of  ciliary  structure:  Electron
microscopy
Analysis of  ciliary  function:
Ciliary  beat  frequency  and  ciliary  beat  pat
with slow-motion-replay  videotape  recorde
and  a  digital  high-speed  video  camera
Other test  Genetic  testing  Original  article
emonstrate  abnormal  structure  and/or  function  of  cilia.30
he  screening  test  and  the  diagnostic  test  should  be  per-
ormed  on  clinically  stable  patients,  free  of  acute  upper
r  lower  respiratory  illness  for  at  least  4--6  weeks  before
ndergoing  measurements  (Table  2).30,32--34
A  lower  threshold  for  screening  should  be  considered  in
ewborn  and  infants  or  when  patient  has  a  consanguineous
ackground.
In  adults  the  diagnosis  of  PCD  should  be  questioned  in  the
bsence  of  BE.28,31
revalence  of  BE  in  PCD
n  a cohort  study  98%  of  adults  and  61%  of  children  with
rimary  ciliary  dyskinesia  had  BE.35
ecommendations
 Patients  with  BE  and  clinical  features  suggestive  of  PCD
should  be  screened  with  nasal  NO  assay  according  to  stan-
dardized  protocol.
 Electron  microscopy  ciliary  structure  analysis  or  video
recording  ciliary  function  analysis  should  be  used  to  con-
ﬁrm  the  diagnosis.
 Genetic  testing  should  not  be  part  of  the  initial  diagnostic
testing.
llergic bronchopulmonary aspergillosis
eﬁnition
llergic  Bronchopulmonary  Aspergillosis  (ABPA)  is  a  non-
nvasive  disorder  caused  by  hypersensitivity  to  a  ubiquitous
ungus  called  Aspergillus  fumigatus  after  inhalation  of  its
pores.36 ABPA  almost  always  occurs  in  patients  with  asthma
r  CF.36 It  is  estimated  that  2%  asthmatics  and  1--15%  of  CF
atients  may  develop  ABPA  but  this  condition  remains  under-
iagnosed  and  the  mean  diagnostic  latency  is  10  years  after
he  onset  of  symptoms.37
ABPA  occasionally  could  complicate  other  chronic  lung
iseases,  namely  idiopathic  BE  or  secondary  to  other
auses.37
Low  nasal  NO  have  high  sensitivity  and
speciﬁcity  after  excluding  CF  in  adults  and
children  at  least  5  years  of  age
Normal  or  high  nasal  NO  can  be  valuable  to
rule out  PCD
Sampling:  nasal  or  bronchial  brushing  or
biopsies  by  forceps
tern
r
If  the  analysis  is  non-conclusive,  it  should
repeat  the  sampling
The  genetic  causes  of  approximately  one-third
of PCD  cases  remain  to  be  explained
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•Recommendations  for  aetiological  diagnosis  of  bronchiectas
Clinical  features
There  is  no  gender  predilection  and  the  majority  of  cases
occur  in  the  3rd  and  4th  decade.
Most  patients  present  with  low-grade  fever,  weight  loss,
worsening  wheezing,  worsening  dyspnoea  and  productive
cough  with  expectoration  of  very  thick  mucus  and  sometimes
well-formed  brownish-black  mucus  plugs.37,38
ABPA  clinical  course  may  evolve  into  5  different  Stages:
Stage  I  --  Active  ABPA;  Stage  II  --  Remission;  Stage  III  --  Recur-
rence  or  exacerbation;  Stage  IV  --  Steroid-dependent  ABPA;
Stage  V  -- Fibro-cavitary  disease.36
Diagnostic  criteria
Laboratory  tests
Total  serum  IgE  levels  >1000  IU/mL  are  the  hallmark  of
ABPA38 (except  in  patients  already  on  systemic  corticoste-
roids)  and  are  also  the  most  useful  test  for  follow-up.  A
doubling  of  patient’s  baseline  IgE  levels  indicate  relapse  of
ABPA.37
A.  fumigatus-speciﬁc  IgE  levels  are  also  elevated  and
recently  were  considered  more  sensitive  than  skin-prick  test
to  Aspergillus  antigen.39,40 The  ideal  is  to  use  a  combination
of  both.39
Peripheral  eosinophilia  (>1000  cells/L),  precipitins  and
other  IgG  antibodies  against  Aspergillus  are  also  supportive
of  diagnosis.38
Imaging
HRCT  demonstrates  central  BE  (varicose  or  cystic)  in  mul-
tiple  lobes  --  ABPA  with  Central  Bronchiectasis  (ABPA-CB),
although  they  could  be  absent  in  some  patients  --  Serolog-
ical  ABPA  (ABPA-S).38 HRCT  may  also  show  mucus  plugging
with  gloved-ﬁnger  shadows  (represent  mucoid  impaction
in  dilated  bronchi),  transient  consolidation,  centrilobular
nodules  with  tree-in-bud  appearance,  atelectasis,  mosaic
perfusion  (areas  of  air-trapping  on  expiration)  and  ﬁbrosis
(in  end-stage  disease).37,38
Sputum  cultures  for  A.  fumigatus
Sputum  cultures  for  A.  fumigatus  are  supportive  but  not
diagnostic.37
There  is  not  a  single  test  to  diagnose  ABPA  nor  is  there
a  universally  established  set  of  criteria,38 but  the  following
are  the  recently  proposed  Revised  Criteria:41
Obligatory  criteria  (all  mandatory):
•  Asthma  or  CF
•  Elevated  total  serum  IgE  (>1000  IU/mL)
•  Elevated  Aspergillus-speciﬁc  IgE  levels  or  skin-prick  test
positive  to  Aspergillus
Other  criteria  (at  least  2  mandatory):
•  Presence  of  precipitins  or  IgG  antibodies  against  A.  fumi-gatus  in  serum
•  Peripheral  eosinophilia  (>500--1000  cell/L) in  steroid-
naïve  patients
•  Radiographic  ﬁndings  consistent  with  ABPA:
•227
 Transient  (consolidations;  centrilobular  nodules;  ﬁnger-
in-glove  opacities)
 Permanent  (central  BE;  pleuropulmonary  ﬁbrosis)
If  the  patient  meets  all  other  major  and  minor  criteria,
n  IgE  value  <  1000  IU/mL  may  be  acceptable.
revalence  of  BE  in  ABPA
he  prevalence  of  BE  in  ABPA  ranges  from  69  to  78%  in  dif-
erent  studies.42
ecommendations
 All  patients  with  BE  should  be  screened  for  sensitization
to  A.  fumigatus  with  speciﬁc  IgE  antibody  or  skin-prick
test.
 If  one  of  the  above  mentioned  screen  tests  is  positive,
total  IgE  level  should  be  measured.
 A  total  IgE  >  1000  IU/mL  or  in  its  absence  a  worsening  of
dyspnoea,  wheezing  or  of  productive  cough  should  prompt
the  remaining  diagnostic  tests.
ystic ﬁbrosis and cystic ﬁbrosis related
isorders
eﬁnition
F  is  the  most  common  autosomal  recessive  disease  among
aucasian  populations.43,44
It  is  caused  by  mutations  in  the  cystic  ﬁbrosis  transmem-
rane  conductance  regulator  (CFTR)  gene,  that  results  in
ysfunction  of  the  apical  membrane  CFTR  protein,  which
egulates  chloride  and  sodium  transport  in  secretory  epithe-
ial  cells,  leading  to  abnormal  ion  concentrations  across  the
pical  membranes  of  these  cells.45
CF  is  a  multissistemic  disease.  It  is  associated  to  a  large
umber  of  mutations  (>2000),46 responsible  for  different
ypes  of  dysfunction  of  the  CFTR  protein  and  consequently
ith  a  wide  variability  of  fenotipic  expression.47
The  term  ‘CFTR-related  disorders’  is  used  to  describe  a
linical  entity  which  is  also  associated  with  CFTR  dysfunc-
ion,  but  that  does  not  fulﬁl  all  the  diagnostic  criteria  for
F.48 Three  main  clinical  entities  illustrate  these  pheno-
ypes:
 CBAVD  (congenital  bilateral  absence  of  the  vas  deferens)
 Acute  recurrent  or  chronic  pancreatitis
 Disseminated  BE
linical  features
linical  features  and  their  prevalence  in  CF  patients
nclude:49,50
 Disseminated  BE  --  95%  (chronic  colonization  with  cer-
tain  microorganisms  such  as  Staphylococcus  aureus  and
Burkholderia  cepacea  complex  being  very  suggestive  of
this  disease)
 Sinus  disease  with  panopaciﬁcation  of  the  sinuses  --
90--100%
2•
•
•
•
•
•
•
•
s
a
p
a
u
D
T
•
•
•
•
•
•
s
t
t
C
g
d
P
T
u
p
a
m
c
a
R
•
•
•
•
•
P
D
P
g
t
f
n
g
q
i
c
a
a
a
o
d
C
T
d
q
r
q
o
h
i
p
s
a
A
B
v
c
t
i28  
 Pancreatic  exocrine  insufﬁciency,  leading  to  malabsorp-
tion  --  85%
 Sweat  gland  salt  loss  --  100%
 Male  infertility  (absent  or  altered  vas  deferens)  --  99%
 Meconium  ileus  --  20%
 Distal  intestinal  obstruction  syndrome  --  20%
 CF-related  diabetes  --  20%
 CF  liver  disease  --  20%
 Nasal  polyps  --  10%
However,  many  patients  demonstrate  mild  or  atypical
ymptoms,  with  less  severe  pulmonary  disease  and  pancre-
tic  sufﬁciency  and  clinicians  should  remain  alert  to  the
ossibility  of  CF  even  when  only  a  few  of  the  usual  features
re  present.44
The  clinical  features  of  the  CFTR  related  disorders  are
sually  restricted  to  only  one  organ  or  system.
iagnostic  criteria
he  criteria  to  establish  the  diagnosis  of  CF  are:51
 one  or  more  of  the  characteristic  phenotypic  features  or
 a  history  of  CF  in  a  sibling  or
 a  positive  neonatal  screening  test  result
And
 an  increased  sweat  chloride  concentration  (>60  mmol/l)
or
 identiﬁcation  of  two  CF  mutations  or
 demonstration  of  abnormal  nasal  epithelial  ion  transport
As  CF  is  associated  with  a  more  rapid  progression  and  con-
iderably  greater  mortality  than  non-CF  BE,  it  is  important
o  identify  these  cases.18
The  diagnosis  of  disseminated  BE  with  CFTR  dysfunc-
ion  can  only  be  admitted  in  the  presence  of  at  least  one
FTR  mutation  and  after  rolling  out  other  possible  aetiolo-
ies  including  a  mild  form  of  CF,  which  can  be  extremely
ifﬁcult.48
revalence  of  BE  in  CF
he  true  prevalence  of  BE  among  children  with  CF  is
nknown;  however,  studies  have  shown  that  50--70%  of
atients  have  HRCT-deﬁned  bronchiectasis  by  3--5  years  of
ge.52 Once  present,  BE  persists  and  progresses  in  approxi-
ately  75%  of  young  children,  despite  receiving  of  the  best
urrent  therapy  and  by  adulthood  the  prevalence  raises  to
pproximately  95%.
ecommendations
 All  children  presenting  with  BE  will  need  investigations  to
exclude  CF.
 Adults  presenting  with  BE  will  need  investigations  to
exclude  CF  especially  if  the  following  clinical  features  are
found:
a
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◦  Gastrointestinal  malabsorption
◦  Male  primary  infertility
◦  History  of  childhood  steatorrhoea
◦ Persistent  isolation  of  Staphylococcus  aureus  in  sputum
◦  Upper  lobe  bronchiectasis
 Screening  investigations  should  include  two  measure-
ments  of  sweat  chloride  (i.e.  quantitative  test)  and  CFTR
genetic  mutation  analysis.
 In  patients  with  BE  with  no  obvious  aetiology  atypical  CF
and  CFTR  dysfunction  related  BE  should  be  considered.
 In  case  of  positive  or  borderline  sweat  tests  patient  should
be  referred  to  a  specialist  CF  centre.  The  same  should  be
done  in  patients  with  negative  sweat  tests  but  a  strong
clinical  suspicion  of  CF.53
rimary immunodeﬁciencies
eﬁnition
rimary  immunodeﬁciencies  (PIDs)  are  a  heterogeneous
roup  of  rare  and  complex  diseases  that  include  more
han  230  different  disorders  caused  by  ineffective  immune
unction  resulting  from  different  mechanisms.54 Predomi-
antly  antibody  deﬁciencies  constitute  the  most  prevalent
roup  of  PIDs.54,55 These  include  the  PIDs  that  more  fre-
uently  present  with  BE  as  sequelae  of  recurrent  chest
nfections3,56,57 particularly  common  variable  immunodeﬁ-
iency  (CVID),  speciﬁc  antibodies  deﬁciency,  X-linked  or
utossomic  recessive  agammaglobulinaemia,  IgA  deﬁciency
nd  Good  syndrome.
PID  recognition  is  crucial  for  early  diagnosis  and
ppropriate  access  to  treatment,  limiting  infections  and  sec-
ndary  structural  damage.  Considering  PID  is  the  key  to
iagnosis.58
linical  features
he  hallmark  of  PID  is  infection.  Patients  with  antibody
eﬁciencies  present  with  recurrent  infections,  most  fre-
uently  caused  by  encapsulated  bacteria  and  affecting  the
espiratory  tract.  These  infections,  besides  increased  fre-
uency,  typically  fail  regular  treatment  and  become  chronic
r  evolve  to  severe  complications.58
CVID  is  the  most  prevalent  symptomatic  PID  in  adult-
ood  (1:50,000  inhabitants  in  western  countries).59 Besides
nfections,  other  features  may  be  found  in  CVID,  including
rolonged  or  recurrent  diarrhoea  and/or  different  expres-
ions  of  autoimmunity  or  lymphoid  proliferation.
Speciﬁc  antibody  deﬁciencies  are  much  more  rare  and
re  frequently  associated  with  complicated  BE.  In  2008,
gamohammadi  et  al.  reported  that  30%  of  the  patients  with
E  classiﬁed  as  idiopathic  presented  decreased  response  to
accination,  allowing  their  aetiologic  reclassiﬁcation  as  spe-
iﬁc  antibody  deﬁciency.60
PID  diagnosis  is  often  missed  when  speciﬁc  antibody
esting  is  not  performed  in  patients  with  recurrent  chest
nfections  and  normal  levels  of  total  serum  IgG.60Agammaglobulinaemia  is  a  PID  characterized  by  the
rrest  of  B  cell  differentiation,  leading  to  a  considerably
educed  B  lymphocyte  count  and  very  low  serum  Ig  levels.
nfections  usually  start  occurring  between  3  and  6  months
Recommendations  for  aetiological  diagnosis  of  bronchiectasis  229
Table  3  PID  characteristics.
Disease  Serum  immunoglobulins  Speciﬁc  Ab/response
to  vaccines
Associated  features
CVID  ↓IgG  and  IgA,  Normal  or  ↓IgM  ↓  >2  years  old
May  present  autoimmunity  and
lymphoid  proliferation
Speciﬁc antibody
deﬁciency
Normal
May  present  ↓IgA  and/or  IgG
subclass  deﬁciency
↓  Frequent  diagnosis  delay  because
total  IgG  is  normal
Agammaglobulinaemia  All  markedly  decreased  ↓  <2%  of  B  cells
Symptoms  <  5  years  old
IgA deﬁciency ↓  IgA;  Normal  IgG  and  IgM Normal  Increased  frequency  of  allergy  and
autoimmunity
Good syndrome  Usually  all  ↓  ↓  Timoma
T  cell  defects  similar  to  HIV  infection
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lof  age,  when  maternal  IgG  levels  start  to  decline.  Lifelong
immunoglobulin  replacement  therapy  is  indicated.  Early
treatment  with  IgG  is  essential  to  reduce  the  infections
recurrence  and  severity  although  BE  may  develop  dur-
ing  follow-up  in  patients  with  adequate  IgG  replacement
therapy.61
IgA  deﬁciency  is  the  most  frequent  PID  (1:600  inha-
bitants  in  western  countries),  but  the  vast  majority  of
patients  in  this  group  is  asymptomatic.62 If  IgA  deﬁciency
is  diagnosed  in  a  patient  with  BE,  IgG  subclasses  quantiﬁ-
cation  and  speciﬁc  antibody  testing  must  be  performed.60
IgA  deﬁciency  may  evolve  to  CVID  or  speciﬁc  antibody
deﬁciency.
Good  syndrome  (timoma  with  immunodeﬁciency)  is  a  rare
cause  of  combined  T  and  B  cell  immunodeﬁciency.  Usually
present  in  the  4th  or  5th  decade  of  life  and  clinical  charac-
teristics  are  increased  susceptibility  to  bacterial  infections
with  encapsulated  microorganisms  and  opportunistic  viral
and  fungal  infections.63
The  main  features  of  these  pathologies  are  mentioned  in
Table  3.  Other  causes  of  hypogammaglobulinemia  must  be
excluded.
Several  reports  have  shown  that  IgG  replacement  ther-
apy  should  ensure  serum  IgG  levels  (above  1000  mg/dL)
in  order  to  allow  a  cutback  in  the  progression  of  lung
deterioration  and  decrease  of  severe  bacterial  infections
frequency.64--66
Diagnostic  criteria  --  investigation  of  PID
•  Serum  immunoglobulin  levels  --  IgG,  IgA,  IgM  and  IgE
•  Serum  IgG  subclass  titres
•  Speciﬁc  antibodies  (quantiﬁcation  by  ELISA)  --  total  IgG
and  IgG2 for  pneumococcal  antigens  and  IgG1 for  tetanus
toxoid  antigen
◦  if  low  titters  are  detected,  access  vaccine  response
after  4--6  weeks;  speciﬁc  antibodies  should  increase  >4
times  pre-vaccination  level
•  Peripheral  blood  lymphocyte  main  subpopulations--
including  T  cells  (total  CD3  and  CD4  and  CD8  subpopu-
lations),  B  cells  and  NK  cells
w
i
tAutoimmunity  often  present
revalence  of  BE  in  PID
E  has  been  reported  in  up  to  76%  of  patients  with  CVID,
eing  more  frequent  in  cohorts  with  a longer  diagnosis
elay.  BE  development  in  CVID  has  been  associated  with
evere/recurrent  respiratory  tract  infections  and  history  of
neumonia,67 unregulated  inﬂammation,  lower  numbers  of
emory  B  cells  and  CD4+  T-cell  counts  below  700/l.68
A  study  of  lung  complications  in  30  patients  with  antibody
eﬁciencies  showed  that  53%  had  CT  scans  abnormalities.
ain  abnormality  was  BE  (12/16  patients),  which  was  seen
ore  frequently  (67%)  on  the  right  middle  lobe.57
ecommendations
 All  patients  with  BE  should  have  measurement  of  serum
IgG,  IgA  and  IgM  levels  and  serum  electrophoresis.
 BE  found  in  a  patient  with  IgA  deﬁciency  should  always
prompt  speciﬁc  antibodies  production  evaluation.
 In  patients  with  BE  with  no  obvious  aetiology  speciﬁc  anti-
body  production  should  be  tested.
 The  presence  of  BE  should  be  assessed  in  all  patients  with
PID  and  PID  should  be  considered  in  patients  with  BE.
 Patients  with  PID  should  be  referred  to  an  immunology
specialist.
ontuberculous mycobacterial pulmonary
isease
eﬁnition
nfections  with  nontuberculous  mycobacteria  (NTM)  are
aused  by  a  large  group  of  mycobacterial  species,  with
aried  spectrum  of  pathogenicity,  other  than  those  of  the
ycobacterium  tuberculosis  complex  and  Mycobacterium
eprae.
NTM  are  ubiquitous  bacilli  whose  main  reservoirs  areater  and  soil.  In  this  context  exposure  to  these  organisms
s  constant.69
The  usual  classiﬁcation  of  NTM  is  established  with  respect
o  time  of  growth  in  culture.70
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Slow  growth  of  the  NTM  (>7  days),  more  pathogenic,  have
ycobacterium  avium  complex  as  the  most  frequent  cause
f  pulmonary  NTM  infection.71 Fast-growing  NTM  (<7  days),
ith  a  less  aggressive  range  of  organisms,  can  produce  ill-
ess  with  high  therapeutic  difﬁculty  and  worse  prognosis  as
ycobacterium  abscessus  complex.72
linical  features
ulmonary  involvement  is  the  most  common  disease  man-
festation  of  NTM  infections  (70--90%  of  cases).  The  most
requent  presentation  is  the  chronic  progressive  form,
arely,  hypersensitivity  pneumonitis  (hot  tub  lung).73,74
The  chronic  clinical  presentation  of  nontuberculous
ycobacterial  pulmonary  disease  (NTM-PD)  can  be  sepa-
ated  into  two  relevant  patterns:70
 Patients  with  pre-existing  structural  changes  character-
ized  by  BE  and/or  cavitations  resulting  of  previous  lung
diseases,  especially  in  elderly  men.
 Patients  with  multifocal  nodular  BE  of  slow  evolution  and
without  lung  underlying  disease  in  non-smoking  women
(often  with  abnormalities  of  the  chest  cage  and  low  body
mass  index).
Typical  presenting  symptoms  of  NTM-PD  include  respi-
atory  symptoms  such  as  persistent  cough,  often  purulent
putum,  sometimes  haemoptysis,  dyspnoea  and  systemic
ymptoms  with  asthenia,  weight  loss  and  intermittent
ever.71
BE  are  associated  with  NTM-PD  as  a  predisposing  fac-
or  to  the  disease,  as  well  as  a  result  of  it,  keeping  a
ause  and  effect  cycle  which  contributes  to  worsening
tructural  damage  of  the  airways  with  progressive  clinical
eterioration.75--77
iagnostic  criteria
iven  the  relatively  low  virulence  of  the  NTM,  in  order  to
roduce  disease,  the  host  has  usually  some  level  of  systemic
r  local  immune  deﬁciency.78--80
Although  not  yet  clinically  validated,  ATS/IDSA  proposed
iagnostic  criteria  of  NTM-PD  which  includes  the  following:81
 Suggestive  clinical  picture  and  imaging  ﬁndings
 Exclusion  of  other  similar  diseases  (fungal  disease,  malig-
nancy,  tuberculosis)
 Identiﬁcation  of  NTM:
◦  at  least  two  positive  culture  from  separate  sputum  sam-
ples  or
◦ culture  positive  in  at  least  one  sample  of  bronchial
wash/lavage  or
◦  biopsy  showing  histopathologic  features  (granuloma-
tous  inﬂammation)  and  positive  culture  in  1  sputum
sample  or  1  sample  LBA  or  1  biopsy  samplePatients  who  are  suspected  of  NTM-PD  but  do  not  meet
he  essential  criteria  should  be  kept  under  surveillance  until
rmly  conﬁrmation  or  exclusion  of  this  diagnosis.82
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pidemiology
verall  NTM  infections  have  increased  signiﬁcantly  in  recent
ears.  There  is  however  a  great  variability  between  regions
egarding  the  prevalence  and  isolated  species.83,84
The  incidence  of  tuberculosis  and  NTM  infection  is
nversely  proportional.  In  this  sense  there  has  been  a  sub-
tantial  increase  in  NTM  disease  in  areas  of  low  incidence  of
uberculosis.85
Epidemiological  studies  indicate  the  following  data:86,87
 USA  -- incidence  of  5--6/100,000  year;  prevalence  10--40/
100,000
 Canada  -- prevalence  14.1/100,000
 Australia  --  incidence  3.3/100,000
 Great  Britain  --  incidence  2.9/100,000
In  a  recent  study,  NTM  were  found  in  37%  of  non-cystic
E,  30%  of  which  met  the  NTM  disease  criteria.88
ecommendations
iven  the  strong  association  of  BE  with  NTM  infection  it  is
mportant  to  rule  out  NTM  in  the  following  groups  of  patients
ith  BE:7,15,89
 In  the  initial  evaluation.
 Before  starting  long-term  use  of  macrolides.
 Every  six  months  when  on  long-term  use  of  macrolides.
 In  the  suspicion  of  NTM-PD  (clinical  deterioration
with  unexplained  persistent  respiratory  and  systemic
symptoms  and/or  with  new  inﬁltrated/cavitations  not
responding  to  usual  treatment  with  regular  antibiotics).
 Every  year  when  there  are  no  speciﬁc  risk  factors.
NTM  identiﬁcation  should  be  made:90
 In  sputum,  3  samples,  preferably  taken  in  the  morning,
on  different  days.
 In  BAL/biopsy  when  patients  are  paucibacillary  with  little
or  no  sputum  (nodular  bronchiectatic  type)  and  suspected
of  NTM-PD.
bstructive airway diseases
eﬁnition
he  presence  of  BE  in  a  patient  with  obstructive  airways
isease  may  result  from  the  intersection  of  prevalences  or
 causal  relationship.  Pathophysiologically  it  is  acceptable
o  consider  a  causal  link  but  no  longitudinal  studies  have
roved  this  relationship  yet.2
linical  featureslinically  these  patients  have  increased  systemic  inﬂam-
ation,  poorer  pulmonary  function,  greater  number  and
everity  of  exacerbations,  more  production  and  purulence
f  sputum,  worse  quality  of  life  and  worse  prognosis.2,91
is  
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In  these  syndromes,  the  pulmonary  disorders  where  reﬂux
is  demonstrated  include  cough  and  reﬂux  asthma.  In  idio-Recommendations  for  aetiological  diagnosis  of  bronchiectas
In  COPD,  BE  are  typically  cylindrical,  small  and  multiple,
predominating  in  lung  bases.91 In  asthma,  BE  can  affect  all
lobes  equally.18
Diagnostic  criteria
Diagnosis  of  obstructive  airway  diseases  (asthma  or  COPD)
with  BE  on  high-resolution  CT  without  evidence  of  other
cause.
Prevalence  of  BE  in  obstructive  airway  diseases
Prevalence  of  BE  in  patients  with  COPD  is  highly  variable
(2--74%),91,92 probably  in  relation  with  the  criteria  used  to
deﬁne  BE.  Several  studies  have  conﬁrmed  a  prevalence
of  approximately  50%  in  patients  with  moderate-severe
COPD.91,93,94
The  prevalence  of  BE  in  asthma  is  described  between  17.5
and  28%.18
Recommendations
•  BE  should  be  suspected  in  patients  with  obstructive  airway
diseases  (COPD  and  asthma)  and  frequent  exacerbations.
•  If  clinically  relevant,  other  BE  aetiologies  should  be
excluded.
Diffuse panbronchiolitis
Deﬁnition
Diffuse  panbronchiolitis  (DPB)  is  an  idiopathic  inﬂamma-
tory  disease  that  mainly  affects  the  respiratory  bronchioles,
causing  a  suppurative  and  progressive  severe  obstructive
disorder.  Histologically  it  is  characterized  by  chronic  inﬂam-
mation,  centralized  in  the  respiratory  bronchioles  with
accumulation  of  histiocytes,  neutrophils  and  lymphocytes.
Foamy  macrophages  in  respiratory  bronchioles  wall  and  sur-
rounding  interalveolar  septa  are  one  feature  of  DPB.95
Clinical  features
DPB  is  most  prevalent  in  the  Asian  population  but  there  are
cases  and  small  series  described  in  Caucasians,  Hispanics  and
Afro-Americans.
It  is  usually  diagnosed  in  the  2nd--5th  decade  of  life  and
2/3  of  patients  are  nonsmokers.95
The  ﬁrst  symptom  is  productive  cough  with  abundant
sputum,  followed  by  progressive  exertional  dyspnoea.  More
than  80%  of  patients  have  chronic  paranasal  sinusitis.
The  most  frequently  isolated  pathogen  in  sputum  is  H.
inﬂuenza,  while  infection  with  P.  aeruginosa  is  common  in
later  stages.
The  most  characteristic  laboratory  ﬁnding  is  the  persis-
tent  elevation  of  cold  agglutinins.Pulmonary  function  tests  usually  show  an  obstructive  pat-
tern  and  low  values  of  nasal  nitric  oxide.95,96
Chest  CT  shows  poorly  deﬁned  centrilobular  nodules,
signs  of  air-trapping  and  bronchial  wall  dilation/thickening.
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hanges  are  scattered  but  more  signiﬁcant  in  the  lower
obes.96
Response  to  macrolides  is  excellent.
iagnostic  criteria
ases  deﬁnitely  established  should  fulﬁl  criteria  1,  2  and  3,
long  with  at  least  two  of  criteria  4,  5  and  6.95
 Persistent  cough,  sputum  and  exertional  dyspnoea
 History  of  chronic  paranasal  sinusitis
 Bilateral  diffuse  small  nodular  shadows  on  a plain  chest
radiography  ﬁlm  or  centrilobular  micronodules  on  chest
computed  tomography  images
 Coarse  crackles
 FEV1/FVC  <70%  and  PaO2  <  80  mmHg
 Titre  of  cold  haemagglutinin  ≥  64
 Due  to  its  rarity,  in  Caucasians  diagnosis  should  be  based
on  lung  biopsy.
revalence  of  BE  in  PBD
he  prevalence  of  BE  in  PBD  is  100%  in  advanced  stages.96
ecommendations
 In  a  Caucasian  patient  with  clinical  criteria,  lung  biopsy
should  be  considered.
astro-oesophageal reﬂux disease
eﬁnition
astro-oesophageal  reﬂux  disease  (GERD)  is  a  pathological
ondition  which  develops  when  gastric  reﬂux  causes  qual-
ty  of  life  disturbing/troublesome  symptoms  and/or  local
omplications.
linical  features
ccordingly  to  the  Montreal  Consensus  Conference,97
ERD  manifestations  are  grouped  in  two  big  syndromes:
sophageal  and  extraesophageal  (Fig.  2):
Concerning  esophageal  syndromes,  symptomatic  syn-
romes  can  be  considered  in  an  initial  evaluation.  They
nclude  typical  GERD  symptoms  (retroesternal  burning  and
cid  regurgitation)  and  chest  pain.  An  endoscopic  evalu-
tion  with  biopsy  will  determine  if  there  is  lesion  of  the
sophageal  mucosa  --  syndromes  with  esophageal  injury
Fig.  2).
Within  extraesophageal  syndromes  two  subgroups  were
onsidered  accordingly  to  the  causal  links  observed:  estab-
ished  association  and  proposed  association  (Fig.  2).athic  pulmonar  ﬁbrosis  reﬂux  is  only  considered  a  probable
ssociation.
Other  reﬂux/GERD  associated  pulmonary  diseases  are
eferred  to  in  the  literature98,99 but  the  causal  relationship
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Esophageal syndromes
Symptomatic
syndromes
1.
2.
1. Reflux esophagitis
Reflux stricture
Barrett's
esophagus
Esophageal
adenocarcinoma
Reflux cough
syndrome
Reflux laryngitis
syndrome
Reflux asthma
syndrome
Reflux dental
erosion syndrome
2.
3.
4.
1.
2.
3.
1. Pharyngitis
Sinusitis2.
3.
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Idiopathic
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Recurrent otitis
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Reflux chest pain
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esophageal injury
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dapted  from  Montreal  Consensus.
s  not  established  with  the  same  probability  degree  as  to  the
isted  above.  Among  them  are:
 Pulmonary  aspiration  complications  (lung  abscess,  BE,
aspiration  pneumonitis)
 Chronic  bronchitis
 COPD
 Obstructive  sleep  apnea  syndrome
The  causal  relationship  between  GERD  and  BE  is  contro-
ersial,  especially  in  adults,  but  it  is  recognized  that  GERD
ould  have  a  negative  clinical  impact  on  BE  patients.  Some
tudies  demonstrated  an  association  with  a  poorer  lung  func-
ion  and  a  more  extensive  disease  on  HRCT.100
Physiopathological  mechanisms  that  can  explain  GERD
ulmonary  manifestations  are:101,102
 Vagal  reﬂex  mechanisms  with  bronchospasm  resulting  of
vagal  stimulation  secondary  to  esophageal  acid  content
(reﬂux  asthma  syndrome)
 Stimulation  of  esophageal  vagus  nerve  endings  resulting
in  reﬂex  cough  (reﬂux  cough  syndrome)
 Microaspiration/gastric  reﬂux  to  the  airways  (mechanism
proposed  mainly  on  reﬂux  cough  syndrome  and  not  so
much  on  reﬂux  asthma  syndrome).  It  is  known  that  the
gastric  content  can  be  acidic  or  gaseous.
Extraesophageal  syndromes  show  distinctive  features
rom  esophageal  syndromes  with  reference  to  antireﬂux
herapy  response  and  multifactorial  causes  being  esophageal
eﬂux  only  a  cofactor.
iagnostic  criteria
iagnostic  and  therapeutic  approach  of  extraesophageal
99,101yndromes  associated  GERD  (namely  pulmonary):
 In  patients  with  typical  GERD  symptoms  a  therapeutic
empiric  trial  could  be  done:
P
d
aanifestations.
◦  double  dose  proton  pump  inhibitors  (PPI)  30  min  before
breakfast  and  dinner  for  12  weeks  (ex:  esomeprazole
40  mg;  pantoprazole  40  mg;  lansoprazole  30  mg).
◦  if  symptoms  improve  and  the  patient  is  well  after
the  12  weeks  trial,  extraesophageal  syndrome  can  be
attributed  to  GERD;  PPI  dose  should  be  reduced  and
evolution  assessed.
 In  patients  with  GERD  atypical  symptoms  24-h
oesophageal  pH-testing  with  impedance  study  should
be  performed.  If  the  exam  conﬁrms  the  diagnosis,
therapeutic  trial  can  be  done.  If  not,  an  alternative
cause  for  pulmonary  symptoms  other  than  GERD  must  be
considered.
pidemiology
n  a  study  by  Pasteur  et  al.  considering  several  BE  aetiolog-
cal  factors,  GERD  was  identiﬁed  as  causative  factor  in  4%  of
atients.5
The  reported  GERD  prevalence  in  the  Western  world
anges  between  10  and  20%.103
Recently,  an  observational  prospective  study,  conducted
o  determine  the  prevalence  of  proximal  and  distal  gastro-
sophageal  reﬂux  in  COPD  and  BE  patients,  showed  that  it
as  2 times  higher  when  compared  to  a  control  population.
he  prevalence  of  GERD  in  BE  was  40%,  of  whom  42%  had
linically  silent  reﬂux.104
ecommendations
 GERD  should  be  suspected  in  the  presence  of  typical
symptoms  or  patients  with  poorly  controlled  respiratory
symptoms.rotection  of  human  and  animal  subjects.  The  authors
eclare  that  no  experiments  were  performed  on  humans  or
nimals  for  this  study.
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